title: Incidence rate of injection-site granulomas resulting from the administration of luteinizing hormone-releasing hormone analogues for the treatment of prostatic cancer.
abstract: OBJECTIVE
  Granulomas resulting from the administration of luteinizing hormone-releasing hormone analogues (LH-RH analogues) are thought to be very rare. We report on our clinical experience with injection-site granulomas that result from the administration of LH-RH analogues, and we evaluate the incidence rate of these granulomas.
  
  
  METHODS
  We used the clinical records of 118 patients who were administered LH-RH analogues in 2005. We describe the clinical data of patients who experienced injection-site granulomas and evaluated the incidence rate.
  
  
  RESULTS
  Five patients demonstrated injection-site granulomas due to LH-RH analogue administration. The incidence rate was 4.2% (5 of 118 patients). Most of the granulomas occurred after the first or second administration of 11.25mg of leuprorelin acetate.
  
  
  CONCLUSIONS
  The occurrence of granulomas resulting from the administration of LH-RH analogues was thought to be very rare. Our study, however, revealed a higher incidence rate than expected, especially for leuprorelin acetate.
authors.affiliation: Department of Urology, Saga Prefectural Hospital, 1-12-9, Mizugae, Saga, 840-0054, Japan. shiota1976@yahoo.co.jp
authors.forename: Masaki
authors.initials: M
authors.lastname: Shiota
authors.forename: Noriaki
authors.initials: N
authors.lastname: Tokuda
authors.forename: Takehiro
authors.initials: T
authors.lastname: Kanou
authors.forename: Humio
authors.initials: H
authors.lastname: Yamasaki
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects; D017252:CD3 Complex / Q000032:analysis; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives; D017273:Goserelin / Q000008:administration & dosage / Q000009:adverse effects; D006099:Granuloma / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007279:Injections, Subcutaneous / Q000009:adverse effects; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D018931:Antineoplastic Agents, Hormonal; D017252:CD3 Complex; D007987:Gonadotropin-Releasing Hormone; D017273:Goserelin; D016729:Leuprolide; C067980:CD68 antigen, human; D000097382:CD68 Molecule